Urovant Sciences (NASDAQ:UROV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “

UROV has been the subject of several other research reports. SunTrust Banks initiated coverage on shares of Urovant Sciences in a research report on Friday, March 15th. They issued a “buy” rating and a $24.00 target price for the company. HC Wainwright initiated coverage on shares of Urovant Sciences in a research report on Monday, March 11th. They issued a “buy” rating and a $28.00 target price for the company. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $21.13.

Urovant Sciences stock traded down $0.50 during midday trading on Wednesday, hitting $7.83. 854 shares of the stock were exchanged, compared to its average volume of 56,294. Urovant Sciences has a 1 year low of $4.05 and a 1 year high of $14.49.

In other Urovant Sciences news, major shareholder Patrick Machado acquired 21,608 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was acquired at an average price of $7.54 per share, with a total value of $162,924.32. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Holdings Ltd. Dexxon acquired 11,608 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were acquired at an average cost of $7.10 per share, with a total value of $82,416.80. The disclosure for this purchase can be found here.

Several large investors have recently made changes to their positions in the stock. Weiss Multi Strategy Advisers LLC grew its position in shares of Urovant Sciences by 38.2% during the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock valued at $99,000 after buying an additional 4,146 shares during the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Urovant Sciences in the first quarter worth approximately $49,000. Barclays PLC purchased a new stake in shares of Urovant Sciences in the fourth quarter worth approximately $37,000. Two Sigma Investments LP purchased a new stake in shares of Urovant Sciences in the fourth quarter worth approximately $72,000. Finally, Northern Trust Corp purchased a new stake in shares of Urovant Sciences in the first quarter worth approximately $111,000. 22.77% of the stock is owned by institutional investors and hedge funds.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Featured Story: Trading Strategy Methods for Individual Investors

Get a free copy of the Zacks research report on Urovant Sciences (UROV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Urovant Sciences (NASDAQ:UROV)

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.